Background
==========

Triple-A syndrome (also known as Allgrove syndrome, OMIM \#231550) is a rare, autosomal recessive disease characterized by alacrima, achalasia, ACTH-resistant adrenal insufficiency, autonomic dysfunction and neurodegeneration. \[[@B1],[@B2]\] Ophthalmic manifestations include alacrima and keratoconjunctivitis sicca, sometimes resulting in corneal melt; lacrimal gland atrophy; pupillary abnormalities, including sluggish pupils, tonic pupils, and hypersensitivity to dilute miotics; and optic atrophy. \[[@B3]-[@B8]\] The phenotype in triple-A syndrome patients is highly variable. \[[@B9]\] Mutations in the *AAAS*gene on chromosome 12q13 have been described in several pedigrees with triple-A syndrome (Table [1](#T1){ref-type="table"}). \[[@B7],[@B9]-[@B19]\] Molecular data coupled with a detailed ophthalmic examination have not be reported in the literature.

We report a case and a novel mutation in the *AAAS*gene in a 12 year-old boy with triple-A syndrome who exhibited evidence of accommodative spasms, in addition to dry eye and pupillary hypersensitivity to 0.125% pilocarpine.

Case presentation
=================

Clinical studies
----------------

The subject was examined at the National Eye Institute and the National Institute of Child Health and Human Development at the National Institutes of Health. Informed parental consent and subject assent were obtained prior to examination and molecular studies. This study was performed in accordance with the Declaration of Helsinki.

Pupillography was performed using a standard pupilometry eye tracking system (ISAN Co, Burlington, Massachusetts). Pupil diameter was digitized at 60 Hz; binocular 150 ms stimuli delivered by green LEDs were used to elicit the light reaction.

Genetic studies
---------------

Analysis of *AAAS*mutations was performed as follows: Genomic DNA was isolated from whole blood following standard procedures. Intronic primers (Invitrogen) were appropriately chosen in order to sequence both splice sites of each exon. Primer sequences are available upon request. PCR products of each exon were run on agarose gels, specific bands were cut and the DNA was isolated following standard procedures. This DNA was sequences in both directions using a Beckman Coulter CEQ8000 following the manufacturer\'s protocol.

History and examination
-----------------------

The subject was diagnosed with adrenocortical insufficiency with elevated plasma ACTH at age 1 after a hypoglycemic seizure and was subsequently pharmacologically supplemented with glucocorticoids. Mineralocorticoid supplementation was initially instituted, but was subsequently discontinued. He cried without tears since birth. At age 2 he developed achalasia, which was treated successfully with surgery. The diagnosis of triple-A syndrome was made at age 4. Pregnancy and birth history were unremarkable. The subject was previously diagnosed with accommodative esotropia and treated with hyperopic correction. The proband\'s parents and three siblings did not have similar symptoms and were healthy. The parents\' grandparents were from the same town in Italy, but there was no known consanguinity. The subject had speech delay as a child and receives speech therapy. He is currently enrolled in a normal 5^th^grade class with special aids for English, social studies and math. Over the past few years, he has developed ataxia. Review of systems was notable for photophobia and dry mouth.

Physical examination was remarkable for a fissured, dry tongue; palmar and plantar keratosis; +4 upper- and lower-extremity reflexes; 3--4 beats of lower-extremity clonus; a positive Babinski sign; and ataxic responses to tandem gait and finger-to-nose testing. The subject did not have orthostatic hypotension. Nerve conduction studies were not performed. An echocardiogram and an electrocardiogram were normal. CT of the abdomen was remarkable for little to no adrenal gland tissue. MRI of the brain showed no abnormalities, but the main lacrimal glands appeared small bilaterally (Figure [1](#F1){ref-type="fig"}).

Visual acuity with his current spectacles (+3.25+1.50 × 120 OD, +3.25+1.50 × 100 OS) was 20/200 OD and 20/150 OS. Manifest refraction of -0.25+1.00 × 120 OD and +0.75 + 1.25 × 60 OS improved acuity to 20/50 and 20/70, respectively. Near vision at 14 inches was J7 OD and J3 OS. The subject had 400\" of stereopsis on Titmus testing and had a red-green color deficiency (saw 3 of 15 Ishihara plates with each eye). Ocular motility was full and without nystagmus. Alternate cover testing with his current spectacles showed a 16--18 PD esotropia (ET) at 1/3 m and an 8 PD ET at 6 m. When allowed to wear a +3.00 D over his current refraction for several minutes, his ET decreased at near to 2--3 PD. Near point of accommodation was 11 cm OD and 9 cm OS. The patient had a somewhat variable, 35--40 ET at distance and near without correction. Clinically, his pupils were 5 mm OD and 5.5 mm OS and were somewhat sluggishly reactive to light. However, his light reaction to LED stimuli recorded with pupillography showed a relatively normal wave form. There was no afferent pupillary defect and constriction at near was not tested. The right pupil was tested with 0.125% pilocarpine and showed constriction to 2.5 mm in approximately 10 minutes. Schirmer testing results with anesthesia were 6 mmOD and 12 mmOS. Slit lamp examination was remarkable for trace injection, a decreased tear lake, and mild, bilateral superficial punctate keratopathy. Intraocular pressures were 11 mm Hg OD and 15 mmHg OS. His optic nerves, vessels, maculae, and retinal peripheries were normal on dilated examination. Cycloplegic refraction was +2.75 + 1.75 × 70 OD and +3.00 + 1.00 × 120. With this refraction, the subject could read 20/50 OD and 20/70 OS. After approximately 1 year of spectacle correction and amblyopia treatment, the subject\'s best-corrected vision improved to 20/30 OD and 20/40 OS. His stereopsis improved to 100 seconds of arc and his performance on Ishihara color-plate testing was stable.

Molecular testing
-----------------

After informed consent, 5 cc of blood was drawn for research purposes. Sequencing of all 16 coding exons of the *AAAS*gene revealed compound heterozygosity for two mutations, both of which are predicted to premature stops in translation. In exon 9, the nonsense mutation leads to a shortened protein of 286, instead of 546, amino acids. In exon 15, and out-of-frame 5-bp deletion, c1368-1372delGCTCA, leads to a premature stop codon and a shortened protein of 492 amino acids (Figure [2](#F2){ref-type="fig"}.) Because both sequence changes are expected to result in premature truncation of the *AAAS*protein, they are likely pathological. This sequence alterations were not present in 100 control chromosomes from unaffected individuals.

Discussion
==========

We present the case of an 12 year-old boy with classic triple-A syndrome who is a compound heterozygote for mutations in the *AAAS*gene. One mutation (R286X) has been previously reported and the other (c1368-1372delGCTCA) is novel. \[[@B11]\] The ophthalmic features consistent with the diagnosis of triple-A syndrome in this patient included: decreased tear production with a history of no spontaneous tearing; superficial punctate keratopathy; and increased pupillary sensitivity to 0.125% pilocarpine. In addition, the subject also appeared to inappropriately accommodate, as comparison of the uncyclopleged manifest refraction and the cycloplegic refraction suggested. This is not likely to be simply manifestation of his accommodative esotropia, *per se*. Although his esotropia improved with hyperopic correction, his vision did not until accommodation was pharmacologically blocked or until a compensatory refraction was given.

Accommodation results from contraction of the ciliary muscles, relaxation of the lens zonules, and an increase in the effective refracting power of the lens. This process is mediated via cholinergic, parasympathetic motor fibers. Patients with triple-A syndrome often manifest signs of autonomic dysregulation, including decreased lacrimation, pupillary abnormalities, orthostatic hypotension, sexual impotence, disturbances of heart rate, and abnormal reactions to intradermal histamine. \[[@B5],[@B7]\] We hypothesize that the refractive difficulties experienced by our subject are related to autonomic dysfunction. Alternatively, because patients with triple-A syndrome have a neurodegenerative process that can affect cranial nerves, \[[@B14]\] the observed dysregulation may be due to central causes.

The decreased best-corrected visual acuity in this boy may have been due to superficial punctate keratopathy and/or amblyopia. Patients with triple-A syndrome sometimes develop optic atrophy. \[[@B7]\] Although our patient did not have clinical evidence of optic nerve dysfunction, we cannot rule out a subtle process that produced a moderate degree of visual impairment, despite the normal appearance of both the optic nerves and brain imaging. Similarly, it is possible that photoreceptor dysfunction in the retina -- while never reported in triple-A syndrome -- could explain some of the decreased best-corrected visual acuity and his red-green color deficiency. The patient was not available for follow-up testing with an electroretinogram, but his improvement with spectacle correction and amblyopia treatment over a year time argues against a progressive photoreceptor degeneration.

Lacrimation -- both reflex and basal -- is under parasympathetic control, as is pupillary miosis. \[[@B20]-[@B22]\] Autonomic dysfunction at the level of the lacrimal glands and the pupil presumably explain the abnormalities seen in this condition. Mullaney *et al*. noted small lacrimal glands on orbital imaging and a reduced number of serous-secreting cells on lacrimal gland biopsy of three patients with triple-A syndrome. \[[@B4]\] The hypersensitivity to dilute pilocarpine is likely due to up-regulation of post-synaptic muscarinic receptors on the iris sphincter. Frequent ocular lubrication was recommended to this subject.

The *AAAS*gene contains 16 exons and codes for a 546 amino acid protein called ALADIN. \[[@B10]\] ALADIN does not have major homology to any known proteins, but contains four WD motifs. WD proteins are a functionally diverse family whose members are involved in processes such as cell division, cell-fate determination, transcription, transmembrane signaling and intracellular trafficking. \[[@B23]\] Proteomic analysis of the mammalian nuclear pore complex (NPC) has shown that ALADIN is part of this structure, which is critical for communication between the nucleus and the cytoplasm of cells. \[[@B24]\] When mutated, ALADIN localizes to the cytoplasm, rather than the NPC. \[[@B25]\] However, cells from a subject with triple-A syndrome showed morphologically normal NPCs. These findings suggest that ALADIN is likely critical for nuclear pore function, rather than NPC structure. ALADIN may therefore be critical for the development of maintenance of the cell types affected in triple-A syndrome. Reshmi-Skarja *et al*. recently described chromosome and/or chromatid breaks, whole chromosome arm deletions, and marker chromosomes involving 9q12, a heterochromatic region know to be a fragile site, in subjects with triple-A syndrome \[[@B17]\].
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![MRI of the brain of 12 year-old boy with triple-A syndrome showing hypoplastic lacrimal glands (yellow arrows.)](1471-2415-4-7-1){#F1}

![Compound heterozygous mutations in *AAAS*gene in subject with triple-A syndrome. The subject has a novel, five base-pair deletion in exon 15 (A, deletion boxed in control panel) predicted to cause a frameshift and a premature truncation of the Aladin protein. He also had a cytosine to thymidine mutation (B) in exon 9, predicted to cause a premature stop of protein translation.](1471-2415-4-7-2){#F2}

###### 

Reported mutations in the *AAAS*gene in subjects with triple A syndrome. The numbering of nucleotides corresponds to the conventions of Dunnen and Antonarakis. \[26\] The most commonly-reported mutation is IVS 14+1G\>A.

  **[Position]{.ul}**   **[Protein]{.ul}**   **[cDNA Mutation]{.ul}**   **[References]{.ul}**
  --------------------- -------------------- -------------------------- ----------------------------------------------------------------------------------------------------------
  IVS 4                                      IVS 4-2A\>G                Tullio-Pelet et al. (2000)
  Ex 9                  R312X                934C\>T                    Tullio-Pelet et al. (2000)
  Ex10                  S328fsX363           981_982insT                Tullio-Pelet et al. (2000)
  IVS 14                                     IVS 14+1G\>A               Tullio-Pelet et al. (2000), Sandrini et al. (2001); Reshmi-Skarja et al (2003); Roubergue A et al (2004)
  Ex 16                 R478X                1432C\>T                   Tullio-Pelet et al. (2000); Yuksel et al. (2004)
  Ex 1                  Q15K                 43C\>A                     Handschug et al. (2001), Sandrini et al. (2001), Houlden et al. (2002); Prpic et al. (2003)
  Ex 2                  W84X                 251G\>A                    Handschug et al. (2001)
  Ex 6                  H160R                479A\>G                    Handschug et al. (2001)
  Ex 6                  F157fsX171           470_471delTT               Handschug et al. (2001)
  Ex 8                  S263P                787T\>C                    Handschug et al. (2001), Houlden et al. (2002); Prpic et al. (2003)
  Ex 15                 S463fsX549           1389delC                   Handschug et al. (2001)
  Ex 9                  R286X                856C\>T                    Handschug et al. (2001), this report
  Ex 11                 R342X                1024C\>T                   Handschug et al. (2001)
  Ex 9                  W295X                884G\>A                    Schmittmann-Ohters (2001)
  IVS 11                                     IVS 11+1G\>A               Sandrini et al. (2001)
  Ex 16                 R478X                1432C\>T                   Goizet et al. (2002), Yuksel et al. (2004)
  Ex 8                  Q237X                709C\>T                    Katsumata et al. (2002)
  Ex 2                  I70fsX92             210delC                    Houlden et al. (2002)
  Ex 7                  R230X                678C\>T                    Houlden et al. (2002), Reshmi-Skarja et al. (2003)
  Ex 10                 V313A                1238T\>C                   Houlden et al. (2002)
  Ex 11                 L356fsX362           1066-1067delCT             Houlden et al. (2002)
  Ex 12                 S382fsX413           1144-1147delTCTG           Houlden et al. (2002)
  Ex 12                 D368fsX382           1104-1105insC              Houlden et al. (2002)
  Ex 13                 397fxs27             1191insA                   Houlden et al. (2002)
  Ex 16                 W474X                1421G\>A                   Houlden et al. (2002)
  Ex 12                 Q387X                1159C\>T                   Prpic et al. (2003)
  Ex 2                  H71fsX92             211delC                    Reshmi-Skarja et al. (2003)
  Ex 4                  R119X                355C\>T                    Reshmi-Skarja et al. (2003)
  Ex 5                  Q145X                433C\>T                    Reshmi-Skarja et al. (2003)
  IVS 5                                      IVS 5+3insT                Reshmi-Skarja et al. (2003)
  Ex 15                 Q456X                1366C\>T                   Reshmi-Skarja et al. (2003)
  Ex 15                 X492                 1368-1372delGCTCA          this report
